Abstract
Restless legs syndrome (RLS) is a neurologic condition that involves an urge to move legs typically accompanied by symptoms of “creeping,” “crawling,” “tingling,” or “aching”. Symptoms can occasionally involve the arms or torso as well. One of the central aspects of the condition is that these dysesthesias occur more often at rest and in the evening, and are temporarily improved with movement. The relief with movement is often immediate. This can cause initiation and maintenance insomnia resulting in excessive daytime sleepiness.
The prevalence of RLS is approximately 10 % and the prevalence of moderate to severe sufferers is approximately 3 %. The condition is diagnosed primarily by history and has multiple treatment options, ranging from lifestyle changes, medication adjustment, and medication treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18(2):128–47.
Ekbom K, Ulfberg J. Restless legs syndrome. J Intern Med. 2009;266(5):419–31.
Phillips B, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med. 2000;160(14):2137–41.
Phillips B, et al. Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll. Chest. 2006;129(1):76–80.
Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep. 1994;17(8):739–43.
Earley CJ, et al. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med. 2004;5(3):231–5.
Earley CJ, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54(8):1698–700.
Schmidauer C, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol. 2005;58(4):630–4.
Godau J, et al. Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord. 2007;22(2):187–92.
Allen RP, Earley CJ. Defing the pherotype of the resthese legs sychrome (RLS) using a of symptom onset. Sleep Med. 2000;1(1)11–19.
Allen RP, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101–19.
Kemlink D, et al. Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics. 2008;9(2):75–82.
Levchenko A, et al. Autosomal-dominant locus for Restless Legs Syndrome in French-Canadians on chromosome 16p12.1. Mov Disord. 2009;24(1):40–50.
Winkelmann J, et al. Genome wide associate study indenfies novel reflects legs systome susceptbadly loci on 2p14 and 16q12.1. Plos Gnet 2011;7(7). Epub 2011 July 14.
Stefanssan H, et al. A genetic using factor for periodic lab rements in slep. N Engl J Med. 2007;357(7):639:47.
Manconi M, et al. Restless legs syndrome and pregnancy. Neurology. 2004;63(6):1065–9.
Wetter TC, et al. Polysomnographic sleep measures in patients with uremic and idiopathic restless legs syndrome. Mov Disord. 1998;13(5):820–4.
Yasuda T, et al. Restless legs syndrome treated successfully by kidney transplantation—a case report. Clin Transpl. 1986;138.
Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ. 1996;312(7042):1339.
Weinstock LB, et al. Crohn's disease is associated with restless legs syndrome. Inflamm Bowel Dis. 2010;16(2):275–9.
Gjevre JA, Taylor Gjevre RM. Restless legs syndrome as a comorbidity in rheumatoid arthritis. Autoimmune Dis. 2013;2013:352782.
Allen RP, et al. Factor analysis of the International Restless Legs Syndrome Study Group’s scale for restless legs severity. Sleep Med. 2003;4(2):133–5.
Walters AS, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4(2):121–32.
Silber MH, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004;79(7):916–22.
Wang J, et al. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med. 2009;10(9):973–5.
Bayard M, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2011;24(4):422–8.
Garcia-Borreguero D, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675–84.
Allen RP, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12(5):431–9.
Inoue Y, et al. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:326–33.
Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev. 2010;14(5):339–46.
Danoff SK, et al. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest. 2001;120(1):313–6.
Cornelius JR, et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33(1):81–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Verma, N., Kushida, C.A. (2014). Restless Legs and PLMD. In: Pagel, J., Pandi-Perumal, S. (eds) Primary Care Sleep Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1185-1_30
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1185-1_30
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1184-4
Online ISBN: 978-1-4939-1185-1
eBook Packages: MedicineMedicine (R0)